Josep S. E.
- Country
- Spain
- Department
- Hematología
Research Overview
- Safety and Pharmacokinetics of XMAB24306 with Daratumumab in Relapsed/Refractory Multiple Myeloma Patients
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Phase III Randomized Trial of Bortezomib, Melphalan, Prednisone, Lenalidomide, Dexamethasone, Carfilzomib, and Daratumumab in Elderly Patients with Newly Diagnosed Multiple Myeloma
Data & Insights
Has run more than one trial at 167 of 371 partner sites.
Specializations
Multiple Myeloma Research
Specialized in developing innovative treatment approaches for multiple myeloma, with particular focus on both newly diagnosed and relapsed/refractory cases.
- Novel therapeutic combinations
- CAR T-cell therapies
- Stem cell transplantation protocols
Explores treatment strategies involving monoclonal antibodies and targeted therapies for enhanced patient outcomes.
Lymphoma Treatment
Conducts extensive research in B-cell lymphomas, including diffuse large B-cell lymphoma and Hodgkin lymphoma.
- Advanced stage treatment protocols
- Immunotherapy approaches
- Response-adapted therapy
Investigates novel antibody-drug conjugates and targeted immunotherapies for lymphoid malignancies.
Emerging Therapeutics
Leads research in innovative therapeutic approaches for hematologic malignancies.
- Bispecific antibodies
- Cell-based therapies
- Combination treatment strategies
Focuses on developing personalized treatment approaches for blood cancers resistant to conventional therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.